Glaser J, Mann O, Pausch J
Department of Internal Medicine, Municipal Hospital Kassel, Germany.
Int J Pancreatol. 1994 Jun;15(3):195-200. doi: 10.1007/BF02924194.
The pancreatic duct can be demonstrated today by sonography in about 90% of all persons examined. In 159 persons, aged 18-79 yr, we measured sonographically the pancreatic duct diameter before and after intravenous secretin injection. After secretin stimulation, 20 healthy controls and 90 patients without pancreatic disease showed a distinct pancreatic duct dilatation of 93 and 94% of basal duct diameter lasting only several minutes. No distinct secretin-induced duct enlargement was observed in 35 of 40 patients with chronic pancreatitis. Patients with chronic pancreatitis and circumscript duct stenosis even had a marked and longer-lasting duct dilatation of 156% of basal duct diameter after secretin stimulation. This study showed a high reliability of the sonographic secretin test in the diagnosis of chronic pancreatitis--even in an early stage--recording a sensitivity of 92.5%, a specificity of 93%, and a predictive value of 84%.
如今,在接受检查的所有人中,约90%可通过超声检查显示出胰管。我们对159名年龄在18 - 79岁的人在静脉注射促胰液素前后进行了胰管直径的超声测量。促胰液素刺激后,20名健康对照者和90名无胰腺疾病的患者胰管出现明显扩张,扩张幅度达基础管径的93%和94%,且仅持续数分钟。40例慢性胰腺炎患者中有35例未观察到促胰液素诱导的明显管径增大。患有慢性胰腺炎和局限性胰管狭窄的患者在促胰液素刺激后胰管扩张更为明显且持续时间更长,扩张幅度达基础管径的156%。本研究表明,超声促胰液素试验在慢性胰腺炎诊断中具有较高的可靠性——即使在早期阶段——敏感性为92.5%,特异性为93%,预测值为84%。